Trial Outcomes & Findings for Urology of Virginia Case Series (NCT NCT03035487)

NCT ID: NCT03035487

Last Updated: 2019-05-15

Results Overview

The primary endpoint will be a standardized description using keywords of each biopsy sample region. These descriptions will be recorded during the blinded readings after the procedure to avoid added procedure time and will be used to compare appearance between the modalities. Keywords will be derived from standard lexicons such as PI-RADS for MRI and PRI-MUS for Micro-Ultrasound.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

9 participants

Primary outcome timeframe

For each patient, keywords will be assigned within one week following the patient's procedure.

Results posted on

2019-05-15

Participant Flow

Participant milestones

Participant milestones
Measure
Micro-ultrasound
Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities: * Low resolution transrectal ultrasound examination ("LR-TRUS") * Multi-parametric MRI ("mpMRI") examination performed according to the PI-RADS v2 protocol Ultrasound guided prostate exam using SOC ultrasound system mpMRI guided prostate examination using PI-RADS v2: mpMRI guided prostate examination using standard of care MRI system High-resolution micro-ultrasound guided prostate biopsy
Overall Study
STARTED
9
Overall Study
COMPLETED
9
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Micro-ultrasound
n=9 Participants
Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities: * Low resolution transrectal ultrasound examination ("LR-TRUS") * Multi-parametric MRI ("mpMRI") examination performed according to the PI-RADS v2 protocol Ultrasound guided prostate exam using SOC ultrasound system mpMRI guided prostate examination using PI-RADS v2: mpMRI guided prostate examination using standard of care MRI system High-resolution micro-ultrasound guided prostate biopsy
Age, Categorical
<=18 years
0 Participants
n=9 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
n=9 Participants
Age, Categorical
>=65 years
6 Participants
n=9 Participants
Sex: Female, Male
Female
0 Participants
n=9 Participants
Sex: Female, Male
Male
9 Participants
n=9 Participants
Region of Enrollment
United States
9 participants
n=9 Participants

PRIMARY outcome

Timeframe: For each patient, keywords will be assigned within one week following the patient's procedure.

The primary endpoint will be a standardized description using keywords of each biopsy sample region. These descriptions will be recorded during the blinded readings after the procedure to avoid added procedure time and will be used to compare appearance between the modalities. Keywords will be derived from standard lexicons such as PI-RADS for MRI and PRI-MUS for Micro-Ultrasound.

Outcome measures

Outcome measures
Measure
Micro-ultrasound
n=9 Participants
Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities: * Low resolution transrectal ultrasound examination ("LR-TRUS") * Multi-parametric MRI ("mpMRI") examination performed according to the PI-RADS v2 protocol Ultrasound guided prostate exam using SOC ultrasound system mpMRI guided prostate examination using PI-RADS v2: mpMRI guided prostate examination using standard of care MRI system High-resolution micro-ultrasound guided prostate biopsy
Keyword Description of Each Biopsy Sample
89 percentage significant cancers detected

Adverse Events

Micro-ultrasound

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Manager, Clinical Research

Exact Imaging

Phone: 905-415-0030

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place